Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composite for preventing and curing senile dementia

A technology of Alzheimer's disease and composition, which is applied in the field of biomedicine and can solve problems such as limited maintenance

Active Publication Date: 2012-04-18
ZHUCHENG HAOTIAN PHARMA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The former mainly includes Aricept, Tacrine, etc. These drugs help to improve the clinical symptoms of mild to moderate patients. However, when neurons are lost to a certain extent, the maintenance of this drug is also limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composite for preventing and curing senile dementia
  • Composite for preventing and curing senile dementia
  • Composite for preventing and curing senile dementia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0123] Example 1. Effects of pyrroloquinoline quinone (PQQ) on the level of cognitive and memory abilities in rats

[0124] Test animals and groups:

[0125] A total of 60 4-week-old Wistar rats (purchased from the Institute of Zoology, Chinese Academy of Sciences) were divided into 5 groups on average, with 12 rats in each group, half male and half male.

[0126] Administration method and dosage:

[0127] According to the following set dose, the grouped rats were orally administered for 8 weeks (twice a day):

[0128] Group 1: Control group was given normal saline;

[0129] Group 2: PQQ 3.3 mg / kg / d (administered in the form of PQQ in normal saline solution);

[0130] Group 3: PQQ 5.0 mg / kg / d (administered by PQQ in the form of physiological saline solution);

[0131] Group 4: PQQ 10 mg / kg / d (administered by PQQ in the form of normal saline solution);

[0132] Group 5: PQQ 20 mg / kg / d (administered by PQQ in physiological saline solution).

[0133] assessment method:

...

Embodiment 2

[0139] Example 2. Effects of acetylcholinesterase inhibitor huperzine A on the level of cognitive and memory abilities in rats

[0140] Experimental animals, groups and drugs:

[0141] A total of 60 4-week-old Wistar rats (purchased from the Institute of Zoology, Chinese Academy of Sciences) were divided into 5 groups on average, with 12 rats in each group, half male and half male.

[0142] Huperzine A: Huperzine A capsules were purchased from Fudan Fuhua Pharmaceutical Co., Ltd. (the contents of the capsules were dissolved in normal saline for experiments).

[0143] Administration method and dosage:

[0144] According to the following set dose, the grouped rats were orally administered for 8 weeks (twice a day):

[0145] Group 1: Control group was given normal saline;

[0146] Group 2: ChEI 0.1mg / kg / d (administered in the form of huperzine A in normal saline solution);

[0147] Group 3: ChEI 0.2mg / kg / d (administered in the form of huperzine A in normal saline solution);...

Embodiment 3

[0156] Example 3. Combination of pyrroloquinoline quinone (PQQ) with the acetylcholinesterase inhibitor (ChEI) huperzine A or The effect of the combination with coenzyme Q10 (CoQ10) on the level of cognitive and memory abilities in rats

[0157] Test animals and groups:

[0158] A total of 60 4-week-old Wistar rats (purchased from the Institute of Zoology, Chinese Academy of Sciences) were divided into 5 groups on average, with 12 rats in each group, half male and half male.

[0159] Administration method and dosage:

[0160] According to the following set dose, the grouped rats were orally administered for 8 weeks (twice a day):

[0161] Group 1: Control group was given normal saline;

[0162] Group 2: PQQ 3.3mg / kg / d (administered in the form of physiological saline solution);

[0163] Group 3: ChEI 0.2mg / kg / d (administered in the form of physiological saline solution);

[0164] Group 4: PQQ 3.3mg / kg / d+ChEI 0.2mg / kg / d (administered in the form of physiological saline ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a composite for preventing and curing senile dementia, particularly, the invention provides a composite for improving the ability of memory and cognition, which comprises: (a) PQQ (pyrro-quinoline quinone), salt and / or ester which are (is) pharmaceutically or physiologically acceptable; (b) acetylcholinesterase inhibitor; and (c) carrier which can be pharmaceutically or physiologically acceptable, wherein the molar ratio of the group (a) and the group (b) is 1:100-100:1. The invention also provides the method for preparing the composite of the invention, the use of the composite, a kit containing the composite or a medicine box, and the preparation method of the composite. The composite of the invention can effectively and safely improve the ability of memory and cognition, can be optimally used to prevent and cure the senile degenerative neurologic disease.

Description

technical field [0001] The invention relates to the field of biomedicine. More specifically, the present invention relates to a composition, a medicine kit or a health care kit capable of preventing and treating Alzheimer's disease, which contain pyrroloquinoline quinone (PQQ) and acetylcholinesterase etc. as main active ingredients. Each component of the composition functions through different mechanisms respectively, and each component has a significant mutual synergistic promotion effect, and has the effect of improving memory and cognitive ability. Background technique [0002] Currently, the prevalence of senile dementia accounts for about 10% of the population aged 60, of which Alzheimer's disease (Alzheimer Disease, AD) accounts for about 5%. Moreover, with every 5-year-old increase in age, the prevalence of AD will increase twice, and 20% of patients aged 80-85 suffer from senile dementia. [0003] According to statistics, the number of Alzheimer's disease (Alzheim...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K31/4745A61P25/28A61K31/122
Inventor 顾建新恽小婧周蕾
Owner ZHUCHENG HAOTIAN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com